Table 2

NY-ESO-1 antibody responses in 218 patients with prostate cancera.

Clinical Stage Antibody Positive Sera
Proportion Percentage
A 0/9 0%
B 0/28 0%
C 0/41 0%
D1 1/30 3.3%
D2 9/110 8.2%
Total 10/218 4.6%

aThe difference in the frequency of detection of NY-ESO-1 antibody between patients with metastasis (stages D1 and D2, 10/140) and without metastasis (stages A, B, and C, 0/78) was statistically significant (P<0.05). Statistical analysis was performed using Fisher's exact test.